



PHARMACEUTICAL 2022












RealRate

PHARMACEUTICAL 2022





The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Moleculin Biotech Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 269%, being 191% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	72,497
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,622
Liabilities, Non-Current	63
Other Assets	11,255
Other Compr. Net Income	-24
Other Expenses	-6,564
Other Liabilities	1,412
Other Net Income	346
Other Revenues	0
Property and Equipment	338
Research and Development	14,418
Selling, General and Administrative Expense	8,386

Output Variable	Value in 1000 USD
Assets	84,090
Liabilities	5,097
Expenses	16,240
Revenues	0
Stockholders Equity	78,993
Net Income	-15,894
Comprehensive Net Income	-15,906
Economic Capital Ratio	269%

